Abstract Purpose To evaluate the efficacy and safety of an orelabrutinib-based RBTL regimen (rituximab, orelabrutinib, temozolomide, and pomalidomide) as an induction strategy for patients with central nervous system lymphoma (CNSL). Patients and methods We retrospectively analyzed 40 patients with CNSL treated at the Affiliated Hospital of Qingdao University between April 2022 and January 2025, including 28 newly diagnosed and 12 relapsed/refractory patients.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile